Search
# Popular search #
中文站
# Popular search #
To promote interconnectivity among the global diabetes community and to jointly benefit from the latest developments in diabetes research, treatment, technology, and care, the 59th European Association for the Study of Diabetes (EASD) Annual Meeting will take place as a hybrid event from 2 to 6 October 2023, providing the option to join us in person in Hamburg, Germany or online via the Virtual Meeting platform. The in-person meeting will take place at: Hamburg Exhibition and Congresse (Hamburg Messe und Congress). For online attendance, the Virtual Meeting platform can be accessed directly or via the EASD website www.easd.org.
On May 31st, the official website of EASD announced the titles of the selected abstracts for this congress, and clinical data from two global Phase III studies of Gan & Lee's proposed biosimilar insulin glargine have been selected for the Short Oral Discussion, along with two poster presentations displayed onsite in Hamburg on dedicated ePoster viewing terminals. Please pay close attention to this!
Gan & Lee Pharmaceuticals’ biosimilar insulin glargine
1. Efficacy, safety, and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 1 diabetes
Session：SO 66 Insulin therapy can be better and cheaper
Presentation number：808
Presentation type：Short Oral
Presenter：Dr. Elena A Christofides丨Endocrinology Associates, USA
Session time：Oct 5th 14:00-15:00 CEST
Link to the abstract: https://cattendee.abstractsonline.com/meeting/10899/presentation/1682
2. Efficacy, safety, and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 2 diabetes
Session：SO 66 Insulin therapy can be better and cheaper
Presentation number：809
Presentation type：Short Oral
Presenter：Dr. Elena A Christofides丨Endocrinology Associates, USA
Session time：Oct 5th 14:00-15:00 CEST
Link to the abstract: https://cattendee.abstractsonline.com/meeting/10899/presentation/900
GLITTER Study
The first ever global Phase III clinical trial series conducted by a Chinese pharma for a domestically manufactured biosimilar insulin. It was designed to demonstrate that Gan & Lee Pharmaceuticals' insulin glargine Basalin®️ has comparable efficacy, safety, and immunogenicity to the originator reference drug Lantus®️ in patients with type 1 diabetes (GLITTER1 study) and type 2 diabetes (GLITTER2 study). Both two GLITTER studies were randomized, open-label, parallel-controlled trials designed to enroll 576 patients with type 1 diabetes and 567 patients with type 2 diabetes, respectively, to compare the changes in efficacy, safety, and immunogenicity between Basalin®️ and Lantus®️ in patients after 26 weeks of continuous administration.
EASD
The European Association for the Study of Diabetes e.V. (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. The EASD Annual Meeting is one of the largest diabetes-related conferences in the world. Each year, the scientific programme of the conference includes more than 1,200 talks and presentations on the latest results from basic and clinical science in diabetes research discussed by leading experts in the field.
The detailed scientific programme of EASD 2023 and the titles of the selected abstracts have been published on the official website, if you want to get more information, please visit the official website of EASD Annual Meeting 2023 https://www.easd.org.
About Gan & Lee
Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).
In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.